Globally, lancets are being utilized by patients who are affected by endocrine related
complications, cardiovascular issues, and many others. Lancets are being used for
diabetes/glucose test, tests in infants, heel-stick screening tests, as well as for scarred
emergency patients or severely burned patients. The Global Lancet Market is growing at an
exponential rate and it is expected to grow at a CAGR of 11.3% during 2016 to 2022.
The increasing prevalence of diabetes and growing incidence number of contagious and non-
contagious diseases has been the major factor for influencing the growth of the market.
Incidence of contagious diseases is increasing rapidly on a global level. According to the
WHO, it has been calculated that, infectious diseases like plaque which is also known as
black death has an estimated 50 million deaths in the 14th century, this infectious disease
can be a serious disease if not treated, this disease has a case fatality ratio of around 30%-
60%, as of 2013 there were 783 cases worldwide which includes 126 deaths.
The Global Lancet Market appears to be oligopolistic owing to the presence of large players
active in the regional market. The market is also characterized by a reasonable degree of
brand loyalty where establishing a brand name is difficult for newcomers. However, the cost
involved in manufacturing setup is low to medium which discreetly comfort the new entrants
to enter in the market easily. Developments in the medical device industry are made to
simplify the diagnosis, prevention, and treatment of various diseases. One of such device is
lancet, which is capturing a huge market share due to its application. Safety lancets and
personal lancets being the two major types of the lancets are dominating the Global Lancet
Market.
Industry Updates
June, 2016: F. Hoffmann-La Roche AG received European approval of Avastin Drug in
combination with Tarceva for cancer patients with a specific type advance lung cancer.
January, 2016: Catalent Inc., a company involved in biologics announced its research
collaboration with Roche on Smartag(TM) technology. Catalent claims Roche will pay
Catalent an up-front fee of $1 million. Roche to provide additional research funding during
the initial phase of the collaboration between these two companies.
October, 2015: BD announced the acquisition of GenCellBio systems, an Irish biotech
company that has developed proprietary technologies that address key biological analysis
protocols, for an undisclosed consideration. The acquisition is expected to improve the BD’s
Next Generation Sequencing line of products.
August, 2015: Roche Holding AG acquired GeneWEAVE to strengthen offerings in
microbiology diagnostics. Roche will pay GeneWEAVE shareholdsers $190 million upfront
and up to $235 million in contingent product related milestones.
March, 2015: BD completed the acquisition of CareFusion Corporation (CareFusion) for
$12.2 billion. CareFusion will operate as a wholly-owned subsidiary of BD. The acquisition is
intended to enhance the medication management and patient safety solutions provided by
BD.
March, 2015: BD announced the acquisition of CRISI Medical Systems, a medical technology
company focused on providing safety and delivery of IV injectable medications. The
acquisition will strengthen BD’s position in addressing preventable medication errors and
improve care delivery efficiencies.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/2078 .
Global Lancets Market - Competitive Analysis
Many key players involved in this market are keen in introducing new advanced safety
lancets for the treatment of various contagious diseases. HTL-STREFA S.A. accounted for
major market share of global lancet market, with more than 35% of market share. The
large share of the company is attributed to the high demand for safety lancet globally.
Moreover, this company has a strong sales and distribution network and this company also
provides after sales services and help which play a major role in the satisfaction of the
customers. F. Hoffmann-La Roche AG accounts for approximately 22% which can be